# Chase Pharmaceuticals Corp: Form D filings

Chase Pharmaceuticals Corp, a pharmaceuticals company in Washington, DC, filed 7 Form D notices with the SEC between 2011 and 2016. The latest, on March 28, 2016, reports $12 million sold of a $12 million offering to 14 investors.

Find out what Chase Pharmaceuticals Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Chase%20Pharmaceuticals%20Corp%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Chase%20Pharmaceuticals%20Corp&page=%2Fdata%2Fform-d%2Fcompany%2Fchase-pharmaceuticals-corp-1509008)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Chase%20Pharmaceuticals%20Corp%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Chase%20Pharmaceuticals%20Corp&page=%2Fdata%2Fform-d%2Fcompany%2Fchase-pharmaceuticals-corp-1509008)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in District of Columbia](https://specstream.ai/data/form-d/state/district-of-columbia): 247 rows, by operating companies, filed since November 1, 2024, $12.35, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/district-of-columbia
- [Form D filings in Pharmaceuticals](https://specstream.ai/data/form-d/industry/pharmaceuticals): 346 rows, by operating companies, filed since November 1, 2024, $17.30, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 1825 K STREET, NW, SUITE 510, Washington, DC, 20006
- Phone: (202) 223-7002
- Industry: Pharmaceuticals
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1509008

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mar 28, 2016 | New notice | $11,974,004 | $11,974,004 | $0 | 14 | Mar 14, 2016 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000114036116059094/0001140361-16-059094-index.htm) |
| Feb 17, 2016 | Amendment | $3,500,000 | $3,500,000 | $0 | 13 | Aug 5, 2015 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000114036116053439/0001140361-16-053439-index.htm) |
| Feb 17, 2016 | New notice | $106,650 | $0 | $106,650 | 3 | Dec 11, 2015 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000114036116053437/0001140361-16-053437-index.htm) |
| Feb 16, 2016 | New notice | $612,500 | $0 | $612,500 | 1 | Jan 13, 2016 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000114036116053435/0001140361-16-053435-index.htm) |
| Aug 20, 2015 | New notice | $3,000,000 | $3,000,000 | $0 | 12 | Aug 5, 2015 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000114036115032968/0001140361-15-032968-index.htm) |
| May 30, 2014 | New notice | $8,586,000 | $6,137,999 | $2,448,001 | 6 | May 9, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000150900814000001/0001509008-14-000001-index.htm) |
| Jan 5, 2011 | New notice | $1,200,000 | $1,200,000 | $0 | 1 | Nov 23, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1509008/000150900811000001/0001509008-11-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Kathleen N. Clarence-Smith | Executive Officer |  |
| Vikram M. Sudarsan | Director |  |
| Raphael M. Wisniewski | Director |  |
| Stephen N. Cunningham | Director |  |
| Nayan Greg Parekh | Director |  |
| Karoly N. Nikolich | Director |  |
| John M. Reher | Director |  |
| Thomas N. Chase | Executive Officer, Director |  |

[Every Form D from the week of Mar 28, 2016](https://specstream.ai/data/form-d/week/2016-03-28) · [All recent filings in District of Columbia](https://specstream.ai/data/form-d/state/district-of-columbia) · [All recent Pharmaceuticals filings](https://specstream.ai/data/form-d/industry/pharmaceuticals)

Read from SEC EDGAR. Amount sold is what Chase Pharmaceuticals Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).